Long term treatment of IgA nephropathy with cyclosporine A

Citation
V. Chabova et al., Long term treatment of IgA nephropathy with cyclosporine A, RENAL FAIL, 22(1), 2000, pp. 55-62
Citations number
21
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Urology & Nephrology
Journal title
RENAL FAILURE
ISSN journal
0886-022X → ACNP
Volume
22
Issue
1
Year of publication
2000
Pages
55 - 62
Database
ISI
SICI code
0886-022X(2000)22:1<55:LTTOIN>2.0.ZU;2-T
Abstract
20-50% of patients with IgA nephropathy (IgAN) reach end-stage renal failur e. Yet a standard treatment for those with progressive course and/or great proteinuria is lacking. We treated 6 patients with biopsy proven IgAN, prot einuria over 3.5 g/24 h and S-creatinine less than 200 mu mol/L non-respond ing to corticosteroids administered for 3 months. They were given cyclospor ine A (CsA) 5 mg/kg bw/day then titrated aiming at a serum concentration of 70-150 ng/mL for one year tapered to discontinuation in 9 months. Predniso ne 5-10 mg on alternate days was given with CsA. Proteinuria (g/day) decrea sed from 4.66 +/- 0.43 to 1.38 + 0.29 (p < 0.01) after 1 month and to 0.590 .14 (p < 0.001) after 1 year of treatment and remained lower than baseline 2 years from the beginning (1.44 +/- 0.27, p < 0.001). GFR (creatinine clea rance) did not change during the first month (1.25 + 0.21 mL/s vs 1.38 +/- 0.29 mL/s), but decreased after 1 year (1.05 + 0.14 mL/s, p < 0.05). After two years it increased to 1.17 + 0.16, NS from baseline. We also calculated the ratio of proteinuria to the GFR (mg/L) to assess the role of hemodynam ic changes in the decrease of proteinuria. This ratio was 53.80 + 6.47 befo re therapy, it decreased after 1 month (11.56 +/- 1.7, p < 0.05) and furthe r after 1 year (6.78 + 1.45, p < 0.01). Three months after discontinuation it was still 14.32 + 1.00, p < 0.05 from baseline. In conclusion, CsA signi ficantly lowered moderate to high proteinuria in 6 patients with IgAN. Sign ificant decrease of the proteinuria/GFR ratio suggests some non-hemodynamic mechanism of CsA action. The therapy was well tolerated and side-effects w ere not so severe as to require CsA withdrawal.